Host stromal versican is essential for cancer-associated fibroblast function to inhibit cancer growth.
The stroma provides a microenvironment that regulates tumor cell behavior. The extracellular matrix (ECM) has long been recognized to be important in tumor cell behavior, and previous studies have revealed the impact of individual matrix molecules on tumor progression. Although several reports have highlighted some central roles of tumor cell-expressed versican, the role of host stromal versican is not yet understood. In this study, we demonstrate that versican is an important molecule in the functional ECM structure and maintaining cancer-associated fibroblasts, using versican-negative QRsP11 fibrosarcoma cells. By their subcutaneous injection with cre-expressing adenoviruses to versican-floxed mice, we demonstrate that loss of host stromal versican facilitates tumor cell proliferation, and following angiogenesis, decreases cancer-associated fibroblasts, diminishes collagen fibers and alters hyaluronan distribution, concomitant with upregulation of hyaluronan, TGFβ and VEGF-mediated signaling. When the versican V3 variant consisting of G1 and G3 domains was expressed in tumor cells, it was integrated into the ECM, regained collagen fibers and cancer-associated fibroblasts and resulted in successful recovery of tumor growth inhibition, indicating that whatever cells produce, the G1 and G3 domains are adequate for versican function. Collectively, our results indicate a dynamic function of versican in the ECM that regulates tumor cell behavior. A greater understanding of the regulation of versican expression may contribute to the development of cancer therapies.
Institute for Molecular Science of Medicine, Aichi Medical University, Aichi, Japan.|Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Kanda
K
Fanhchaksai
Division of Pathological Biochemistry, Department of Biomedical Sciences, Faculty of Medicine, Tottori University, Tottori, Japan.
Futoshi
F
Okada
Institute for Molecular Science of Medicine, Aichi Medical University, Aichi, Japan.
Naoko
N
Nagai
Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Peraphan
P
Pothacharoen
Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Prachya
P
Kongtawelert
Institute for Molecular Science of Medicine, Aichi Medical University, Aichi, Japan.
Sonoko
S
Hatano
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Shinji
S
Makino
Department of Pharmacology, Kansai Medical University, Osaka, Japan.
Tomoyuki
T
Nakamura
Institute for Molecular Science of Medicine, Aichi Medical University, Aichi, Japan.
Hideto
H
Watanabe
D000818:Animals; D045744:Cell Line, Tumor; D005347:Fibroblasts / Q000502:physiology*; D006801:Humans; D006820:Hyaluronic Acid / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000209:etiology; D015398:Signal Transduction / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology; D053675:Versicans / Q000502:physiology*
D016212:Transforming Growth Factor beta; C508322:VCAN protein, human; D053675:Versicans; D006820:Hyaluronic Acid
angiogenesis; cancer-associated fibroblast; microenvironment; proteoglycan; versican